{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": {
    "pdf_name": "FlublokOnePage"
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2
  },
  "extracted_evidence": [
    {
      "id": "comp_1",
      "quote": "Flublok COMBINES THE ADVANTAGES OF RECOMBINANT TECHNOLOGY WITH A HIGHER DOSE 2 4",
      "relevance_explanation": "This quote supports the claim by explicitly stating that Flublok uses recombinant technology and provides a higher dose, which refers to the increased hemagglutinin (HA) antigen content compared to standard-dose flu vaccines.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "in January 2024, vaccination with a higher dose recombinant flu vaccine may induce a more robust antibody response than egg based standard dose vaccines.",
      "relevance_explanation": "This quote directly links the higher dose of recombinant flu vaccine (such as Flublok) to a more robust antibody response, supporting the claim that increased HA antigen content is associated with greater immunogenicity compared to standard-dose vaccines.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ]
}